Abstract
Hepatitis C virus (HCV) infection represents a global health problem due to its evolution to hepatic cirrhosis and hepatocellular carcinoma. The viral pathogenesis and infectious processes are not yet fully understood. The development of natural viral resistance towards the host immune system represents a mayor challenge for the design of alternative therapeutic interventions and development of viral vaccines. The molecular mechanisms of hepatic fibrosis are well described. New alternatives for the treatment of patients with HCV infection and hepatic cirrhosis are under intensive research. New drugs such as viral protease inhibitors and assembly inhibitors, as well as immune modulators have been studied in clinical trials. Additional alternatives include antifibrotic drugs, which reverse the hepatic cellular damage caused by HCV infection. This review makes reference to viral infective mechanisms, molecular pathways of liver fibrosis and overviews conventional and new treatments for HCV infection and liver fibrosis.
Highlights
La infección crónica por virus de hepatitis C (VHC) afecta a alrededor de 170 millones de personas en el mundo, representando alrededor de 3% de la población total[1]
El tratamiento actual para la infección con hepatitis crónica inducida por VHC consiste en IFN pegilado más ribavirina
En un estudio realizado por Horsmans y cols, se administró isatoribine, un agonista selectivo de TLR7, obteniendo una reducción de ARN de VHC en el plasma de 0,76 log en pacientes sin tratamiento previo
Summary
Nuevos tratamientos para la infección por virus de hepatitis C y el proceso de fibrosis hepática. Alejandro Lugo-Baruqui[1], Carlos Alfredo Bautista López[2], Juan Armendáriz-Borunda[1,2]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.